Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity
Amy C Sherman(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Michaël Desjardins(Centre Hospitalier de l’Université de Montréal), Natalie Izaguirre(Dana-Farber Cancer Institute), Jonathan Krauß, Robert J. Soiffer(Dana-Farber Cancer Institute), Nicole V. Tolan(Brigham and Women's Hospital), Chi‐An Cheng(Brigham and Women's Hospital), David R. Walt(Brigham and Women's Hospital), Nicolas C. Issa(Dana-Farber Cancer Institute), Bruce Bausk, Guohai Zhou(Brigham and Women's Hospital)
Cited by 24
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta‐Analysis
|Clinical Infectious Diseases|2001|969